Cited by 143Down syndrome and intellectual disability researchNeurogenesis and neuroplasticity mechanismsPluripotent Stem Cells Research

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome

Open access
Tang, Xiao-Yan, Xu, Lei, Wang, Jingshen, Hong, Yuan, Wang, Yuanyuan, Zhu, Qian, Wang, Da, Zhang, Xin-Yue, Liu, Chun-Yue, Fang, Kai-Heng, Han, Xiao, Wang, Shihua, Wang, Xin, Xu, Min, Bhattacharyya, Anita, Guo, Xing, Lin, Mingyan, Liu, Yan·2021·Journal of Clinical Investigation

Abstract

Down syndrome (DS), caused by trisomy of chromosome 21, occurs in 1 of every 800 live births. Early defects in cortical development likely account for the cognitive impairments in DS, although the underlying molecular mechanism remains elusive. Here, we performed histological assays and unbiased single-cell RNA-Seq (scRNA-Seq) analysis on cerebral organoids derived from 4 euploid cell lines and from induced pluripotent stem cells (iPSCs) from 3 individuals with trisomy 21 to explore cell-type-specific abnormalities associated with DS during early brain development. We found that neurogenesis was significantly affected, given the diminished proliferation and decreased expression of layer II and IV markers in cortical neurons in the subcortical regions; this may have been responsible for the reduced size of the organoids. Furthermore, suppression of the DSCAM/PAK1 pathway, which showed enhanced activity in DS, using CRISPR/Cas9, CRISPR interference (CRISPRi), or small-molecule inhibitor treatment reversed abnormal neurogenesis, thereby increasing the size of organoids derived from DS iPSCs. Our study demonstrates that 3D cortical organoids developed in vitro are a valuable model of DS and provide a direct link between dysregulation of the DSCAM/PAK1 pathway and developmental brain defects in DS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci135763

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

Sorted by citations

See all 143

Metadata

Authors
Tang, X.-Y., Xu, L., Wang, J., Hong, Y., Wang, Y., Zhu, Q., Wang, D., Zhang, X.-Y., Liu, C.-Y., Fang, K.-H., Han, X., Wang, S., Wang, X., Xu, M., Bhattacharyya, A., Guo, X., Lin, M., & Liu, Y.
Affiliations
  • State Key Laboratory of Reproductive Medicine (CN)
  • Nanjing Medical University (CN)
  • Xiamen University (CN)
  • University of Wisconsin–Madison (US)
Corresponding author
  • Guo, Xing
  • Lin, Mingyan
  • Liu, Yan
Venue
Journal of Clinical Investigation
Published
2021-06-15
Volume
131
Issue
12
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3158718113
Cited by
143
References
64
Citations by year
2026: 16 · 2025: 29 · 2024: 28 · 2023: 34 · 2022: 30 · 2021: 6
FWCI
21.23
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Chinese Academy of Sciences (XDA16010306)
  • Government of Jiangsu Province
  • National Key Research and Development Program of China (2019YFA0802703)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
Down syndrome, Dscam, PAK1, neurogenesis, brain organoids, iPSC-derived organoids, cortical development, CRISPR interference, small molecule inhibitors, cognitive impairment, in vitro disease model
MeSH terms
Cell Line, Cerebral Cortex, Down Syndrome, Humans, Organoids, Signal Transduction, Cell Adhesion Molecules, p21-Activated Kinases, Neurogenesis, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review